266 results about "Metformin" patented technology

The invention relates to an application of metformin in preparation of skin anti-photoaging drugs or medical instruments. Through verification, the metformin has the effects of promoting the formation of autophagosome, recovering the patency of autophagy flow and remodeling an autophagy-ECM metabolism regulation network. After the composition is applied to the skin (such as a corium layer), the effect of resisting skin photoaging is achieved by adjusting an AMPK signal channel. The metformin is used as an active ingredient to prepare a medicine or a medical instrument, and is beneficial to clinically anti-photoaging application of the skin.

The invention discloses an anti-tumor intelligent double-crosslinking hydrogel drug delivery system based on a purple phosphorus nanosheet and a preparation method and application thereof, the system comprises a hydrogel carrier, a photodynamic carrier material and a drug, and the hydrogel carrier is a drug delivery carrier formed by crosslinking polydimethyldiguanide with Fe < 3 + > and a crosslinking agent; the photodynamic carrier material is a purple phosphorus nanosheet; the medicine is a medicine with two effects of inhibiting hypoxia-inducible factor-1 alpha and lowering PD-L1 down. According to the invention, the purple phosphorus nanosheet and the polydimethyldiguanide / Fe < 3 + > bi-crosslinking hydrogel are taken as carriers to prepare the tumor microenvironment response type hydrogel drug delivery system with good pH responsiveness, injectability and self-healing property, so that an effective solution is provided for tumor precise drug delivery mediated by a new material, namely the purple phosphorus nanosheet, as a nano-drug carrier; the invention also provides an effective photodynamic therapy strategy for anti-tumor application of the intelligent double-crosslinking hydrogel and precise treatment of breast cancer.

A liquid composition comprising a GLP-1 agonist or / and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and / or with long-acting insulin / insulin derivates where appropriate.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention relates to the technical field of biomedical materials, in particular to photo-thermal antibacterial healing-promoting hydrogel as well as a preparation method and application thereof. The preparation method of the hydrogel comprises the following steps: dispersing mesoporous polydopamine (MPDA) into a Tris-HCl solution, and then adding L-arginine to prepare L-MPDA; the preparation method comprises the following steps: fully dissolving 3-(aminomethyl) phenylboronic acid hydrochloride and 4-(4, 6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride into hyaluronic acid (HA), regulating the pH value to 6.5 by using alkali liquor to obtain phenylboronic acid modified hyaluronic acid mixed liquor, and dialyzing and freeze-drying to obtain HA-PBA. The preparation method comprises the following steps: dissolving metformin and purified L-MPDA in deionized water, sequentially adding purified HA-PBA and a polyvinyl alcohol (PVA) solution, and uniformly mixing to obtain the hydrogel. The hydrogel prepared by the invention has excellent hemostasis, antibacterial and adhesion properties. When the hydrogel is used as a hydrogel dressing for treating a diabetic wound surface, the healing speed of the diabetic wound surface can be effectively improved.

A method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy-inducing compounds. In one embodiment, the one or more autophagy-inducing compounds are selected from the group consisting of thymol, carvacrol, spermidine, urolithin (e.g., Urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5′ AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g. beta-hydroxybutyrate, ketone salts, or ketone ester derivatives), 4,4′-dimethoxychalcone and mixtures thereof.

The invention discloses a hypoglycemic composition containing supramolecular group composite peptide. The hypoglycemic composition comprises collagen peptide, soybean peptide, bitter gourd peptide, bamboo leaf flavone, L-carnitine and the like. The composition prepared by selecting raw material components of specific types and dosages has the effects of remarkably reducing the glucose level and increasing the insulin level, and part of the composition can also cooperate with metformin to achieve the effects of enhancing the effect of reducing blood sugar and improving or preventing type 2 diabetes mellitus. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The invention discloses injectable hydrogel for treating periodontitis and a preparation method of the injectable hydrogel. The injectable hydrogel is prepared from protocatechuic acid grafted carboxymethyl chitosan hydrogel and a zinc-metformin complex loaded in the protocatechuic acid grafted carboxymethyl chitosan hydrogel. The hydrogel aims to become a safe and effective treatment method so as to reduce oxidative stress and tissue damage caused by periodontitis. And the hydrogel is designed into an injectable form, so that the clinical operation is facilitated, and the comfort of a patient is improved. Therefore, the treatment effect and life quality of patients with chronic periodontitis are improved, and inconvenience and discomfort in the treatment process are reduced.

Described herein, inter alia, are compositions comprising and methods of making and using endothelial cells (ECs) comprising one or more mitophagy-inducing agents (e.g., rapamycin, SKF-96365, lithium, carbamazepine, latrepirdine, spermidine, resveratrol, sodium valproate, trehalose, kaempferol, metformin, AICAR, nilotinib, ambroxol, curcumin, and VL-004). Also described herein, inter alia, are methods vascular cell therapy, promoting blood vessel formation, and increasing vascular development, angiogenesis, and cell junction via administration of a population of ECs comprising a mitophagy-inducing agent (MIA-ECs).

The invention discloses an application of an AMPK (adenosine monophosphate kinase) activator or a PPAR (peroxisome proliferator activated receptor) gamma inhibitor in preparation of a medicine for preventing or treating diabetic osteoporosis. The invention discloses a key effect of a brand new signal channel, namely an AMPK-PPAR gamma-ERS axis, in osteogenic differentiation disorder of diabetes mellitus, and provides a method for preventing and treating diabetic osteoporosis by regulating and controlling the signal axis by taking metformin as a core. The invention provides new guidance for research and development of medicines for treating osteoporosis, and has potential clinical application and mechanism research values.

The invention discloses composite hydrogel and application of the composite hydrogel in preparation of a diabetes wound repair dressing. The gel comprises Metformin (Met) loaded Mg-MOF / Met nano-particles, a hydrogel carrier and a hydrogel carrier, wherein the Mg-MOF / Met nano-particles are prepared from the following components of Mg-MOF / Met nano-particles; the hydrogel network is formed by cross-linking chitosan (CA) modified by arginine and oxidized dextran through a Schiff base reaction; wherein the Mg-MOF / Met nano particles are uniformly dispersed in the hydrogel network, and the Mg-MOF / Met nano particles are uniformly dispersed in the hydrogel network. An animal model verifies that after 14 days, the healing rate reaches 92.1%, the antibacterial rate is larger than 95%, the ROS clearance rate is 85.2%, the cell survival rate is larger than 95%, and remarkable application prospects are shown in the field of diabetes wound repair.

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

The present invention provides a method for cell anti-aging, in which a constructed cell aging model is first treated with mesenchymal stem cells for 12-48 hours, and then metformin is added for 12-48 hours. This combined therapy can significantly enhance the expression level of glutathione peroxidase 7 (GPx7) in aging IMR-90 cells, thereby greatly reversing the aging state of IMR-90 cells.

The invention provides a method for improving mixing uniformity of a medicinal compound preparation of metformin and empagliflozin, and belongs to the technical field of medicines. The invention provides an ultrasonic uniform mixing method for dry granulation. The ultrasonic uniform mixing method adopts an air jet pulverization technology, an ultrasonic-assisted vertical shaft planetary stirrer mixing technology and a forced sieving technology, and adopts a strengthening means; by utilizing the synergistic effect of ultrasound and a mixer, the mixing time is shortened, the mixing effect is enhanced, the uniformity and dissolution rate of the preparation are remarkably improved, and the method is short in process route, simple in step operation, easy in condition control and suitable for large-scale production.

The present invention relates to an immediate release monolithic tablet comprising a) granules comprising Metformin or its pharmaceutically acceptable salt, hydroxypropyl cellulose and at least one more pharmaceutically acceptable excipient, and b) powder mixture consisting essentially of Empagliflozin or its pharmaceutically acceptable salts, low substituted hydroxypropyl cellulose and at least one diluent, wherein said immediate release monolithic tablet doesn't comprise copovidone. The said tablet has a desirable pharmacokinetic characteristic, favorable storage stability and comparative dissolution properties. The invention further relates to a process for the preparation of said pharmaceutical composition and use thereof as medicament in the treatment of diabetes.

The present invention relates to the field of pharmaceutical technology, and in particular to a pioglitazone hydrochloride and metformin compound tablet and a preparation method thereof. The pharmaceutical preparation utilizes ultrasonic technology in combination with a solubility regulator to improve the solubility of pioglitazone hydrochloride, thereby preparing an excellent pioglitazone hydrochloride solid dispersion. The suspension is further prepared and coated around a metformin tablet core by a suspension-loading method. In the present invention, the preparation of the pioglitazone hydrochloride solid dispersion and the loading method are key factors affecting the solubility and uniformity of pioglitazone hydrochloride and metformin. By further optimizing the formulation, controlling the granulation process conditions, and coordinating the solubility of metformin and pioglitazone hydrochloride, a compound tablet with good compounding effect is obtained. The prepared compound tablet has good uniformity, thereby achieving uniform drug dispersion and controlled release.

The invention relates to the technical field of gelatin production, and discloses a method for improving the characteristic that gelatin-based hydrogel is easy to solidify at room temperature. The gelatin-based hydrogel is prepared from the following raw materials: gelatin, a hydrogen bond competitive material and water, the hydrogen bond competitive material is selected from at least one of metformin, L-arginine, an amide micromolecule cross-linking agent, polyarginine and a polyurea compound. According to the gelatin-based hydrogel provided by the invention, the gelation temperature is less than 25 DEG C, the gelatin-based hydrogel is not easy to solidify at room temperature (20-25 DEG C), and compared with a common gelatin solution, the gelatin-based hydrogel has the advantage that the characteristic that the gelatin is easy to solidify at room temperature is improved; according to the preparation method of the gelatin-based hydrogel, the room-temperature coagulability of the gelatin aqueous solution can be improved by introducing a material with competitive hydrogen bonds into the gelatin aqueous solution through simple physical blending, and compared with a traditional covalent modification method, the method is easy to operate and high in applicability, does not damage the original structure of gelatin and is good in repeatability.

The invention discloses application of metformin to improvement of crop seed germination and stress resistance, the metformin is used as a widely used hypoglycemic drug, has a cross-species conservative metabolism regulation function, can activate an antioxidant defense system of plants, maintain K < + > / Na < + > balance in the plants, and can improve the survivability of crops in saline-alkali soil. After the metformin is adopted to treat the seeds, the germination rate and the germination potential of the seeds are obviously improved, the chlorophyll content, the peroxidase content, the soluble protein content and the like of seedlings are obviously increased, the malondialdehyde content is obviously reduced, and the stress resistance is obviously enhanced. The technology is low in treatment cost, simple to operate and obvious in effect.

The utility model discloses a metformin hydrochloride electrochemical analysis device which comprises a shell, and one side of the shell is provided with an electric sensor interface; the power supply unit is arranged in the shell and is used for generating polarization voltage; the silk-screen printing electrode electric sensor is electrically connected with the power supply unit and comprises a flexible electrode base body, a working electrode, a counter electrode, a reference electrode, an insulating layer, a wiring terminal and an electrode connecting wire, and the working electrode, the counter electrode, the reference electrode, the insulating layer, the wiring terminal and the electrode connecting wire are arranged on the flexible electrode base body; the surface of the working electrode is modified with an imprinted polymer with selective recognition on metformin hydrochloride; the signal processing unit is arranged in the shell and comprises a shunt resistor, an operational amplifier, a signal converter, a data storage chip and a microprocessor which are electrically connected in sequence; the display screen is electrically connected with the microprocessor and is used for displaying the converted concentration value; the method has the advantages that the metformin hydrochloride can be rapidly and accurately detected, and the use is relatively convenient.

The application belongs to the technical field of bioactive nanomaterials, and particularly relates to a metformin nanomaterial, a preparation method and application thereof. The average hydrodynamic diameter of the nanomaterial is less than 500 nm, and the nanomaterial is prepared by a preparation method comprising the following steps: self-assembly of metformin and polyphenols to obtain metformin-polyphenol nanoparticles; reaction of bisphosphonate and polyethylene glycol to obtain bisphosphonate-polyethylene glycol organic segments; and reaction of the metformin-polyphenol nanoparticles and the bisphosphonate-polyethylene glycol organic segments to obtain the nanomaterial. The metformin, polyphenol, polyethylene glycol and bisphosphonate are prepared into the metformin-loaded nanomaterial through specific reactions, the systemic delivery of metformin is realized, the efficacy and bioavailability of metformin on osteoporosis are improved, and the bone targeting of metformin is also improved.

The invention provides a dapagliflozin and metformin sustained-release tablet with stable dissolution and a preparation method of the dapagliflozin and metformin sustained-release tablet. Comprising the following steps: S1, respectively preparing metformin hydrochloride particles and dapagliflozin particles; s2, firstly tabletting and forming metformin hydrochloride particles, then adding dapagliflozin particles, and carrying out secondary tabletting, so as to obtain a dapagliflozin and metformin sustained-release tablet core; the mass ratio of the metformin hydrochloride particles to the dapagliflozin particles is (4-10): (0.1-1); and S3, coating the obtained tablet core with a coating solution to obtain the dapagliflozin and metformin sustained release tablet with stable dissolution. According to the dapagliflozin and metformin sustained release tablet, the RSD of the substance content of the metformin hydrochloride layer can reach 0.3%, the RSD of the substance content of the dapagliflozin layer can reach 0.1%, the sum of impurities of the metformin hydrochloride can not be detected, and the total impurity of the dapagliflozin can reach 0.06%. According to the invention, the process and the raw materials are optimally designed, so that the production link is simplified, and the problems of poor quality and the like caused by the distribution difference of the two effective components in the sustained release tablet are solved.

A single-layer tablet comprising linagliptin, or a pharmaceutically acceptable salt thereof, metformin hydrochloride, a diluent, a glidant and a lubricant, wherein the tablet is produced by direct compression.

The application discloses a preparation method of CCR2+ gamma delta T cells with anti-tumor activity and migration ability, and belongs to the technical field of cells; the method comprises the following steps: step (1), PBMC of peripheral blood of a healthy person is extracted, inoculated into complete culture medium, and added with zoledronic acid, IL-15 and metformin, and then is cultured in a T25 culture bottle; step (2), complete culture medium is supplemented, the cell concentration is adjusted, and then the cells are transferred into a T75 culture bottle for culture; step (3), complete culture medium is supplemented, the cell concentration is adjusted, glucocorticoid and nicotinamide are added, and then the cells are transferred into a T150 culture bottle for culture; step (4), cells are collected at D6, rinsed with normal saline, resuspended with complete culture medium, the cell concentration is adjusted, and then the cells are inoculated into a T300 culture bottle for culture; and step (5), complete culture medium is supplemented every two days from D8 to D16, the cell concentration is maintained, and then the cells are harvested at D16 to obtain CCR2+ gamma delta T cells.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of a GLP-1R agonist compound and metformin in preparation of drugs for preventing and / or treating diseases such as diabetes and complications thereof.

The present invention belongs to the technical field of hypoglycemic drugs, and specifically relates to a hypoglycemic pharmaceutical composition, a pharmaceutical preparation and a preparation method thereof. The hypoglycemic pharmaceutical composition and the pharmaceutical preparation comprise metformin hydrochloride, as well as a mixed granule of bitter melon extract and microcrystalline cellulose. The preparation method of the hypoglycemic pharmaceutical preparation comprises the following steps: Step 1, preparing a mixed granule of bitter melon extract and microcrystalline cellulose; Step 2, treating metformin hydrochloride and excipients for standby; Step 3, premixing the raw and auxiliary materials in Step 1 and Step 2; Step 4, sieving and sizing the powder premixed in Step 3; Step 5, adding a lubricant to the sized powder in Step 4 for total mixing; Step 6, tabletting and packaging the granules after total mixing in Step 5. By using the pharmaceutical composition or the pharmaceutical preparation of the present invention, it is possible to prevent and treat diabetes while reducing the incidence of gastrointestinal reactions caused by metformin hydrochloride.

Compositions and methods are provided for the prevention of osteonecrosis or osteoporosis associated with corticosteroid administration in an individual. The methods of the disclosure comprise administration of an effective dose of a metformin agent, or a derivative, mimetic or analog thereof in combination with administration of a corticosteroid. The effective dose of metformin agent decreases oxidative stress and restores osteogenic capacity of mesenchymal stem cells exposed to a glucocorticoid.

A method of treating, reducing, or alleviating a medical condition in a patient includes administering to a patient in need thereof, a pharmaceutical composition comprising one or more antiviral medications together with an anti-vascular endothelial growth factor (anti-VEGF) medication and a rho-associated protein kinase (ROCK) inhibitor, the patient having at least one of a respiratory tract inflammatory disease, a central nervous system inflammatory disease, and vasculitis, the one or more antiviral medications preventing an attachment of viruses to cell walls, blocking a penetration of the viruses into cells, and / or inhibiting virus replication by damaging nucleic acids of the viruses, and the anti-VEGF medication and ROCK inhibitor treating an exhausted cellular immune response and inflammation of the patient. In one or more other embodiments, the pharmaceutical composition comprises one or more antiviral medications together with at least one of: (i) cannabidiol (CBD), (ii) linoleic acid, (iii) catechin, and (iv) metformin.

Compositions including metformin and their use for inhibiting or treating soft tissue musculoskeletal injuries, such as tendinopathy, and / or treating or inhibiting scar tissue are disclosed.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

The invention relates to a linagliptin and metformin sustained-release composition and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the linagliptin and metformin sustained-release composition comprises a metformin sustained-release tablet core and a linagliptin coating layer wrapping the metformin sustained-release tablet core; the linagliptin coating layer accounts for 2-3% of the total mass of the composition; the metformin sustained-release tablet core comprises a plain pellet core, a coating layer and a filling agent; wherein the plain pellet core comprises a large-particle-size pellet core of 1.10-1.25 mm, a medium-particle-size pellet core of 0.80-0.95 mm and a small-particle-size pellet core of 0.50-0.65 mm, and the mass ratio of the large-particle-size pellet core to the medium-particle-size pellet core to the small-particle-size pellet core is 15: 60: 25; through particle size grading, pore differentiation design and hydrophobic modification treatment, the drug release curve is optimized, the release uniformity is improved, and meanwhile, the production stability and the consistency of the preparation are improved.